Inhibikase Therapeutics, Inc. revenue breakdown overview

Inhibikase Therapeutics, Inc. revenue for the last year amounted to 260.50 k USD, the most of which — 260.50 k USD — came from its highest performing source at the moment, Protein Kinase Inhibitor Therapeutics, the year earlier bringing 123.44 k USD. The greatest contribution to the revenue figure was made by United States — last year it brought Inhibikase Therapeutics, Inc. 260.50 k USD, and the year before that — 123.44 k USD.